Emyria Limited is a public healthcare company specializing in the development of innovative medical treatments targeting unmet needs in mental health and select neurological conditions. Founded in 2018 and headquartered in Leederville, Australia, Emyria drives its research and clinical activities through a robust pipeline that includes MDMA-inspired medicines and ultra-pure cannabidiol (CBD) capsules designed for complex pain and anxiety management. These initiatives are guided by real-world clinical data sourced from its wholly owned medical service subsidiaries, enabling evidence-based advancement of new therapies. Notably, Emyria’s therapeutic programs focus on areas such as psychological trauma, Parkinson’s disease, and drug-assisted therapy for mental health disorders. Through strategic collaborations with academic institutions, such as the University of Western Australia, the company enhances its capabilities in drug development for neurodegenerative and psychiatric diseases. Emyria’s integrated approach combines clinical services, data analytics, and pharmaceutical innovation, positioning the firm as a key player within the specialist medical services segment of the healthcare market.